Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

@article{Owen2013ResponseAI,
  title={Response assessment in Waldenstr{\"o}m macroglobulinaemia: update from the VIth International Workshop},
  author={Roger G. Owen and Robert A. Kyle and Marvin J. Stone and Andy C. Rawstron and Véronique Leblond and Giampaolo Merlini and Ram{\'o}n Garc{\'i}a-Sanz and Enrique Mar{\'i}a Ocio and Enrica Morra and Pierre Morel and Kenneth C. Anderson and Christopher J. Patterson and Nikhil C. Munshi and Alessandra Tedeschi and Douglas Edgar Joshua and Efstathios Kastritis and Evangelos Terpos and Irene M. Ghobrial and Xavier Leleu and Morie A. Gertz and Stephen M. Ansell and William G. Morice and Eva Kimby and Steven P P Treon},
  journal={British Journal of Haematology},
  year={2013},
  volume={160}
}
This report represents a further update of the consensus panel criteria for the assessment of clinical response in patients with Waldenström macroglobulinaemia (WM). These criteria have been updated in light of further data demonstrating an improvement in categorical responses with new drug regimens as well as acknowledgement of the fact that such responses are predictive of overall outcome. A number of key changes are proposed but challenges do however remain and these include the variability… Expand
Response Assessment in Waldenström’s Macroglobulinaemia
TLDR
The most updated consensus panel response definitions include evaluation of the monoclonal immunoglobulin M in serum, the tumour burden in bone marrow and in extramedullary sites and symptoms of disease. Expand
Overview on clinical trials in Waldenstrom's macroglobulinemia
TLDR
In younger and fit patients immunochemotherapy should be considered the standard of care as recent data showed an improvement in quality of responses, progression-free and overall survival. Expand
Waldenström macroglobulinemia: Progress in evidence-based medicine and updates of consensus panel recommendation
TLDR
Waldenstrom macroglobulinemia should be differentiated from lymphomas producing monoclonal IgM, and detection of MYD88 L265P mutation provides a new way to differentiate WM from other similar diseases. Expand
Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment
TLDR
Advances have been made recently with the demonstration of a WM-specific (CD22weak CD25+) immunophenotype and the MYD88 L265P mutation in the vast majority of patients, resulting in advances in diagnosis, prognostic assessment and post-treatment response evaluation. Expand
How to manage Waldenstrom's macroglobulinemia
TLDR
This review summarizes the current knowledge about WM and aims at offering a guideline for the clinical management of patients with this lymphoma subtype, covering questions on how to manage diagnosis, prognostification and treatment based on the most recent data. Expand
Waldenström macroglobulinemia at 70
TLDR
This article is intended to chronicle the 70-year development of knowledge, treatment options and limitations that bring us to the authors' current approach to WM, as well as the challenge for international collaboration in order to enable us to develop the most efficient path to optimal patient care. Expand
Waldenström macroglobulinemia: from biology to treatment
TLDR
Many of the novel agents discussed have shown good responses and have a better toxicity profile compared to traditional chemotherapeutic agents, which makes them good candidates to be used as primary therapies for WM in the future. Expand
Current therapy guidelines for Waldenstrom's macroglobulinaemia.
TLDR
The BTK inhibitor ibrutinib was recently approved for patients with Waldenstrom's macroglobulinaemia, and is a new option for selected newly diagnosed or relapsing patients. Expand
Waldenstrom's macroglobulinemia in the era of immunotherapy
Abstract Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma that presents with symptomatic anemia, thrombocytopenia, constitutional symptoms, extramedullary disease and rarelyExpand
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016
TLDR
A multidisciplinary team appraised studies published or presented up to December 2015 to provide consensus recommendations for a risk-adapted approach to Waldenström macroglobulinemia, using a grading system, and advises participation in clinical trials, if available, at every stage of WM. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.
TLDR
The criteria have been updated to include minor response and stable disease categories and recognize that delayed responses after treatment with nucleoside analogues and biologic agents and the time point for assessing response in patients with WM should be considered so as to not miss or miscategorize a response. Expand
Assessment of bone marrow response in Waldenström's macroglobulinemia.
TLDR
Persistent monoclonal plasma cells were readily identified by CD138 immunohistochemistry, explaining the persistence of serum M protein in patients with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma. Expand
Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
TLDR
Recommendations for uniform response criteria for use in assessing responses to treatment for patients with Waldenstrom's macroglobulinemia were prepared in conjunction with the Second International Workshop held in Athens, Greece during September 2002. Expand
Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow‐up of the Eastern Cooperative Oncology Group E3A98 trial
TLDR
Patients achieving a minor response appeared to do as well as those achieving an objective response (>50% IgM reduction), which suggests that more aggressive or intensive therapy for minor responders is not required. Expand
Novel M-component based biomarkers in Waldenström's macroglobulinemia.
TLDR
Hevylite measures IgMkappa and IgMlambda, separately, and might provide true quantitative measurement of the IgM M-spike, although current data are preliminary, Hevylites might replace the current technique to measure IgMM-sp spike in the years to come. Expand
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
This presentation represents consensus recommendations for the clinicopathological definition of Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the Second InternationalExpand
Residual monotypic plasma cells in patients with waldenstrom macroglobulinemia after therapy.
TLDR
It is concluded that WM can persist as a pure plasma cell population after therapy, which has implications for the immunophenotypic assessment of WM after therapy and may explain persistent IgM paraproteinemia in patients with WM with no evidence of a clonal B-lymphocyte population. Expand
Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248
TLDR
The results of these studies show that bortezomib is an active agent in relapsed and refractory WM and sensory neuropathies resolved or improved in nearly all patients following cessation of therapy. Expand
The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia
TLDR
Involved sFLC may be a useful marker of tumor measurement, showing earlier response and progression compared with IgM or M-spike measurements, and a flare in iFLC in post–rituximab therapy did not correlate with lack of response or shorter TTP. Expand
Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia.
TLDR
During follow-up post-treatment, seven delayed responses were observed, improving the initial overall response rate from 61% to a final response rate of 77% in patients treated with fludarabine with or without cyclophosphamide. Expand
...
1
2
3
4
...